Notice of Proposed Sale · 144
Contineum Therapeutics, Inc.
CTNMNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Contineum Therapeutics, Inc.
- Issuer CIK
- 0001855175
- SEC file number
- 001-42001
- Phone
- 8583335280
- Person for whose account securities are to be sold
- Daniel Lorrain
- Relationships to issuer
- Officer
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 4,170 | 55,961.40 | 32,958,632 | 10/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 05/09/2017 | Restricted Stock Units | Issuer | 4,170 | N | 05/09/2017 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for DANIEL LORRAIN | Common | 09/01/2026 | 9,520 | 154,895.52 |
| 10b5-1 Sales for DANIEL LORRAIN | Common | 08/03/2026 | 9,520 | 151,792.08 |
| 10b5-1 Sales for DANIEL LORRAIN | Common | 07/31/2026 | 127 | 2,032.00 |
| 10b5-1 Sales for DANIEL LORRAIN | Common | 07/09/2026 | 25 | 400.00 |
| 10b5-1 Sales for DANIEL LORRAIN | Common | 07/08/2026 | 1,015 | 16,240.00 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for DANIEL LORRAIN
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for DANIEL LORRAIN
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Seller — prior-sale row 3, entry 1
- Name
- 10b5-1 Sales for DANIEL LORRAIN
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Seller — prior-sale row 4, entry 1
- Name
- 10b5-1 Sales for DANIEL LORRAIN
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Seller — prior-sale row 5, entry 1
- Name
- 10b5-1 Sales for DANIEL LORRAIN
- Street
- 3565 General Atomics Court, Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Daniel Lorrain
- Plan adoption dates
- 09/23/2025
Company context
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit www.contineum-tx.com.